サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1742514

糖尿病前症の世界市場：製品タイプ別、年齢層別、エンドユーザー別、地域別、機会、予測、2018年～2032年

Prediabetes Market Assessment, By Product Type, By Age Group, By End-user, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 264 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
糖尿病前症の世界市場：製品タイプ別、年齢層別、エンドユーザー別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月06日
発行: Market Xcel - Markets and Data
ページ情報: 英文 264 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖尿病前症の市場規模は、2025年～2032年の予測期間中に9.06％のCAGRで拡大し、2024年の3億3,054万米ドルから2032年には6億6,129万米ドルに成長すると予測されています。糖尿病前症は、肥満の増加、遺伝的要因、高齢化社会の拡大、加工食品や糖分の多い飲食品の消費の拡大により増加しています。国際糖尿病連合（International Diabetes Federation）の推計によると、2050年までに8億5,300万人の成人が糖尿病に罹患するとされています。

糖尿病の早期発見と2型糖尿病への移行を予防するための介入の重要性に対する一般人口と医療専門家の意識の高まりが、市場の需要をさらに押し上げています。人口の増加により、糖尿病前症に関連する製品やサービスの需要が非常に高まっています。肥満の増加、不健康な食事、座りっぱなしのライフスタイルは、糖尿病のリスクをさらに高めています。そのため、市場の大手企業は、新製品の連続グルコースモニタリングの発売に注力しています。例えば、2024年9月、Abbott Laboratoriesは、インスリンを服用せず、健康増進を望む成人向けの市販（OTC）持続グルコースモニター（CGM）であるLingoを発売しました。

当レポートでは、世界の糖尿病前症市場について調査し、市場の概要とともに、製品タイプ別、年齢層別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の糖尿病前症市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 製品タイプ別
      • 診断およびデバイス
      • 医薬品および治療薬
      • 栄養補助食品と機能性食品
      • その他
    • 年齢層別
      • 子供
      • 大人
      • 高齢者
    • エンドユーザー別
      • 病院と診療所
      • 診断センター
      • 在宅ケア
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米の糖尿病前症市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の糖尿病前症市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の糖尿病前症市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の糖尿病前症市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの糖尿病前症市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

  • 製品の発売と承認
  • 革新
  • 臨床試験

第18章 政策と規制状況

第19章 ケーススタディ

第20章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • Ascensia Diabetes Care Holdings AG
    • Omada Health, Inc.
    • Noom, Inc.
    • Eli Lilly and Company
    • PharmaLinea nutraceuticals, Ltd.
    • Oramed Pharmaceuticals Inc.
    • Bayer AG

第21章 戦略的提言

第22章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 3. Global Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 4. Global Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 5. Global Prediabetes Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 7. North America Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 8. North America Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 9. North America Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 10. North America Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 12. United States Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 13. United States Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 14. United States Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 15. Canada Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 16. Canada Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 17. Canada Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 18. Canada Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 19. Mexico Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 20. Mexico Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 21. Mexico Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 22. Mexico Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 23. Europe Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 24. Europe Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 25. Europe Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 26. Europe Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 27. Europe Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Germany Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 30. Germany Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 31. Germany Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 32. France Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 33. France Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 34. France Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 35. France Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 36. Italy Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 37. Italy Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 38. Italy Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 39. Italy Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 40. United Kingdom Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 41. United Kingdom Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 42. United Kingdom Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 43. United Kingdom Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 44. Russia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 45. Russia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 46. Russia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 47. Russia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 48. Netherlands Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 49. Netherlands Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 50. Netherlands Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 51. Netherlands Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 52. Spain Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 53. Spain Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 54. Spain Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 55. Spain Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 56. Turkey Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 57. Turkey Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 58. Turkey Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 59. Turkey Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 60. Poland Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 61. Poland Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 62. Poland Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 63. Poland Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 64. South America Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 65. South America Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 66. South America Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 67. South America Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 68. South America Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Brazil Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 71. Brazil Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 72. Brazil Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 73. Argentina Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 74. Argentina Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 75. Argentina Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 76. Argentina Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 77. Asia-Pacific Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 78. Asia-Pacific Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 79. Asia-Pacific Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 80. Asia-Pacific Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 81. Asia-Pacific Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 82. India Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 83. India Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 84. India Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 85. India Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 86. China Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 87. China Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 88. China Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 89. China Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 90. Japan Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 91. Japan Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 92. Japan Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 93. Japan Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 94. Australia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 95. Australia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 96. Australia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 97. Australia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 98. Vietnam Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 99. Vietnam Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 100. Vietnam Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 101. Vietnam Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 102. South Korea Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 103. South Korea Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 104. South Korea Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 105. South Korea Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 106. Indonesia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 107. Indonesia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 108. Indonesia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 109. Indonesia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 110. Philippines Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 111. Philippines Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 112. Philippines Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 113. Philippines Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 114. Middle East & Africa Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 115. Middle East & Africa Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 116. Middle East & Africa Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 117. Middle East & Africa Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 118. Middle East & Africa Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 120. Saudi Arabia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 121. Saudi Arabia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 122. Saudi Arabia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 123. UAE Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 124. UAE Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 125. UAE Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 126. UAE Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 127. South Africa Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 128. South Africa Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 129. South Africa Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 130. South Africa Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 131. By Product Type Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 132. By Age Group Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 133. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024
目次
Product Code: MX13260

Global prediabetes market is projected to witness a CAGR of 9.06% during the forecast period 2025-2032, growing from USD 330.54 million in 2024 to USD 661.29 million in 2032. Prediabetes cases are increasing due to rise of obesity, genetics factors, expansion of the aging population and increasing consumption of processed foods and sugar rich beverages. As per the estimate of the International Diabetes Federation, 853 million adults will have diabetes by 2050.

Increasing awareness among the general population and healthcare professionals about the importance of early detection of the condition and intervention to prevent the progression to type 2 diabetes is further propelling the market's demand. The rising population increases the demand of prediabetes-related products and services tremendously. Increasing obesity, unhealthy diet, and sedentary lifestyle are further increasing the risk of diabetes. Thus, leading market players are focusing on launching new products continuous glucose monitoring. For instance, in September 2024, Abbott Laboratories, launched Lingo, an over-the-counter (OTC) continuous glucose monitor (CGM) for adults that do not take insulin and want to improve their health.

Technological Advancement Supports Market Expansion

Technological advancements are driving the growth of the prediabetes market by enhancing diagnostic and monitoring capabilities, such as continuous glucose monitoring systems and digital health solutions. It also provides accurate and personalized treatment approaches by adding artificial intelligence (AI) and machine learning tools for quick results and provide relief for both patient and the healthcare provider. These innovations facilitate better management and awareness of prediabetes, addressing the rising incidence of lifestyle-related disease. Innovations in CGM systems, smartphone apps, portable glucometers and AI detection tools enhance the early detection of glucose irregularities and prevention from Type 2 diabetes. Almost half of all adults with diabetes are not aware that they are suffering from it, thus, leading players in the market are focusing on launching advanced diabetes detection tools. For instance, in November 2024, Redcliffe labs launched a digital diabetes risk checker tool on its official android app.

Increasing Research Activities Support Market Expansion

Ongoing clinical trials and research studies are expanding the understanding of prediabetes and allowing researchers to develop new therapies such as GLP-1 receptor agonists and combination therapies, which show promise in improving glycemic control and reducing associated risks. Research into biomarkers and advanced technologies like CGM are improving diagnostic precision and patient management. Various research institutions are focusing on developing programs that allow patients to reverse their prediabetes with lifestyle changes. For instance, in December 2024, a new program was launched in the St. John's region in Canada to assist individuals in reversing their progression toward type 2 diabetes. The four-week program is available across different YMCAs across Canada and is expected to aid patients in reversing their prediabetes with dietary changes and exercise.

Adults Hold Major Market Share

As per the age group adults have more diabetes due to the unhealthy lifestyle, obesity, genetics factors and lack of more consumption of fresh food products. As per the estimates of the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes.

Individuals in this age group are more inclined to participate in regular health screenings, workplace wellness initiatives, and digital health monitoring, which contribute to the early identification and diagnosis of prediabetes. As healthcare professionals increasingly prioritize prevention and long-term health results, there is a heightened focus on early intervention, especially among younger individuals, to postpone or avert the development of type 2 diabetes. The rising use of fitness trackers, health applications, and telehealth services among adults aged 18-49 has also facilitated proactive health monitoring and lifestyle management, promoting early diagnosis and involvement in preventive healthcare.

North America Dominates the Prediabetes Market

North America is exerting its dominance in the prediabetes market due to a combination of high prevalence rates, advanced healthcare systems and effective public health strategies. In North America millions of adults are affected by prediabetes, creating significant demand for screening, diagnosis and treatment options. They enjoy robust healthcare infrastructures that facilitate early detection, preventive services, and insurance support. Initiatives such as the CDC's National Diabetes Prevention Programs (NDPP), along with considerable funding and public awareness efforts, further enhance market's expansion. Furthermore, North America is at the forefront of digital health innovation, evidenced by the extensive adoption of remote monitoring technologies, AI-powered applications, and interconnected devices deployed by companies such as Omada Health Inc. and Livongo (Teladoc Health, Inc.) are allowing for easy management of diabetes. Investment from the private sector in diabetes prevention and management technology also bolsters the region's prominence in this field.

Leading players in the reasons are focusing on launching new products and technology to reduce the burden of diabetes. For instance, March 2025 Tandem Diabetes Care, Inc. introduced its upgraded Control-IQ+ automated insulin delivery system in the United States.

Impact of U.S. Tariffs on Global Prediabetes Market

The tariffs imposed by the U.S. have introduced significant challenges for the prediabetes market and are expected to affect the accessibility and affordability of essential diagnostic and blood glucose monitoring tools that are essential in diabetes management. Additionally, tariffs are disrupting supply chains, leading to delays or shortages in the distribution of these products.

In response to the tariffs, leading pharmaceutical companies are investing in expanding their manufacturing base in the United States to reduce their reliance on imports. However, changes in manufacturing locations can trigger additional compliance requirements, resulting in delays in the introduction of new products and technologies.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of prediabetes market globally, the market is driven by escalating prevalence of prediabetes and strong preference for preventive healthcare. To maintain their position in the market the key players are investing in innovation and research activities as well as nutraceuticals and functional foods. They collaborate with academic institutes and partner with pharmaceutical companies, tech firms and health care providers to integrate care modals.

For instance, in August 2024, Eli Lilly and Company announced favorable initial findings from the SURMOUNT-1 three-year trial assessing the effectiveness and safety of tirzepatide administered once a week for long-term weight management and delaying the onset of diabetes in adults with pre-diabetes and obesity or overweight.

Similarly, in March 2023, Pharma Linea Nutraceuticals Ltd launched Prediabetiq capsule to provide immediate improvements in glycemic response that can be easily measured in real-time.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Prediabetes Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Diagnostics and Devices
        • 5.2.1.1.1. Blood Glucose Monitoring Devices
        • 5.2.1.1.2. Point-of-Care Testing (POCT) Devices
        • 5.2.1.1.3. Testing Kits
        • 5.2.1.1.4. Others
      • 5.2.1.2. Pharmaceuticals and Therapeutics
        • 5.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
        • 5.2.1.2.2. Insulin Sensitizers
        • 5.2.1.2.3. Others
      • 5.2.1.3. Nutraceuticals and Functional Foods
        • 5.2.1.3.1. Blood Sugar Control Supplements
        • 5.2.1.3.2. Weight Management Supplements
        • 5.2.1.3.3. Others
      • 5.2.1.4. Others
    • 5.2.2. By Age Group
      • 5.2.2.1. Children
      • 5.2.2.2. Adults
      • 5.2.2.3. Elderly
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals and Clinics
      • 5.2.3.2. Diagnostic Centers
      • 5.2.3.3. Homecare Settings
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product Type
    • 5.3.2. By Age Group
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. North America Prediabetes Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Product Type
      • 6.2.1.1. Diagnostics and Devices
        • 6.2.1.1.1. Blood Glucose Monitoring Devices
        • 6.2.1.1.2. Point-of-Care Testing (POCT) Devices
        • 6.2.1.1.3. Testing Kits
        • 6.2.1.1.4. Others
      • 6.2.1.2. Pharmaceuticals and Therapeutics
        • 6.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
        • 6.2.1.2.2. Insulin Sensitizers
        • 6.2.1.2.3. Others
      • 6.2.1.3. Nutraceuticals and Functional Foods
        • 6.2.1.3.1. Blood Sugar Control Supplements
        • 6.2.1.3.2. Weight Management Supplements
        • 6.2.1.3.3. Others
      • 6.2.1.4. Others
    • 6.2.2. By Age Group
      • 6.2.2.1. Children
      • 6.2.2.2. Adults
      • 6.2.2.3. Elderly
    • 6.2.3. By End-user
      • 6.2.3.1. Hospitals and Clinics
      • 6.2.3.2. Diagnostic Centers
      • 6.2.3.3. Homecare Settings
      • 6.2.3.4. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Prediabetes Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
    • 6.3.2. By Product Type
      • 6.3.2.1. Diagnostics & Devices
        • 6.3.2.1.1. Blood Glucose Monitoring Devices
        • 6.3.2.1.2. Point-of-Care Testing (POCT) Devices
        • 6.3.2.1.3. Testing Kits
        • 6.3.2.1.4. Others
      • 6.3.2.2. Pharmaceuticals and Therapeutics
        • 6.3.2.2.1. Metformin and Oral Antidiabetics (OADs)
        • 6.3.2.2.2. Insulin Sensitizers
        • 6.3.2.2.3. Others
      • 6.3.2.3. Nutraceuticals and Functional Foods
        • 6.3.2.3.1. Blood Sugar Control Supplements
        • 6.3.2.3.2. Weight Management Supplements
        • 6.3.2.3.3. Others
      • 6.3.2.4. Others
    • 6.3.3. By Age Group
      • 6.3.3.1. Children
      • 6.3.3.2. Adults
      • 6.3.3.3. Elderly
    • 6.3.4. By End-user
      • 6.3.4.1. Hospitals and Clinics
      • 6.3.4.2. Diagnostic Centers
      • 6.3.4.3. Homecare Settings
      • 6.3.4.4. Others
    • 6.3.5. Canada
    • 6.3.6. Mexico

All segments will be provided for all regions and countries covered

7. Europe Prediabetes Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Prediabetes Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Prediabetes Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Prediabetes Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

  • 17.1. Product Launches and Approvals
  • 17.2. Innovation
  • 17.3. Clinical Trials

18. Policy and Regulatory Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Abbott Laboratories
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. F. Hoffmann-La Roche Ltd.
    • 20.3.3. Siemens Healthineers AG
    • 20.3.4. Ascensia Diabetes Care Holdings AG
    • 20.3.5. Omada Health, Inc.
    • 20.3.6. Noom, Inc.
    • 20.3.7. Eli Lilly and Company
    • 20.3.8. PharmaLinea nutraceuticals, Ltd.
    • 20.3.9. Oramed Pharmaceuticals Inc.
    • 20.3.10. Bayer AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer